Made worse
8%The contributor reported that symptoms became worse during or after rifaximin.
This is a broad patient outcome label. It does not identify a named adverse reaction or prove that rifaximin caused the change.
Rifaximin (Xifaxan) side effects and patient outcomes
Compare what people reported across 1,378 gut-health stories: clear help, partial help, no change, or feeling worse. See the SIBO, IBS, and other contexts around those experiences.
The short answer
The results are divided, and lack of benefit is more commonly reported than a clear success. “Made worse” remains visible instead of being folded into a generic unsuccessful group.
See the splitPatient-reported outcome ledger
No change is the largest reported outcome.
Among 1,358 outcome-bearing rifaximin/Xifaxan reports, 22% were rated helped, 21% partially helped, 49% no change, and 8% made worse.
Made worseNo changePartially helpedHelped
8%
Made worse
Symptoms were reported as worse; this is not a named clinical side effect.
49%
No change
The structured outcome recorded no reported improvement.
21%
Partially helped
Some benefit was reported, but symptoms or limits remained.
22%
Helped
The story reported a clear benefit.
These are structured patient reports, not clinical response rates, prescribing guidance, or proof that rifaximin caused a particular result.
Why people reported taking it
Rifaximin is not only a SIBO story.
GutPattern groups stories by treatment history first. SIBO is the largest reported context, while IBS and SIBO subtypes also appear. These rows overlap: one story can carry more than one diagnosis or test label.
US drug references also list travelers’ diarrhea, hepatic encephalopathy, and IBS-D uses. This page does not invent separate outcome rates for uses the GutPattern dataset cannot isolate reliably.
SIBO
73%1,004
stories with this reported context
IBS
22%310
stories with this reported context
Hydrogen SIBO
15%211
stories with this reported context
Methane SIBO / IMO
12%161
stories with this reported context
Context counts describe the same broad rifaximin cohort. They are not mutually exclusive treatment indications.
GutPattern outcome signal
“Made worse” does not mean “clinical side effect.”
8% of outcome-bearing reports were labeled made worse. That can capture symptoms worsening during or after treatment, but the aggregate does not identify a specific adverse reaction or prove causation.
Named drug-reference side effects
Use clinical references for the medical list.
MedlinePlus lists effects such as stomach pain, dizziness, tiredness, headache, muscle tightening, and joint pain, plus serious warning signs that need prompt medical attention. Those references answer a different question from GutPattern’s patient outcome labels.
How to read the four outcomes
Each outcome answers a different question.
The categories preserve important differences between intolerance, lack of benefit, incomplete benefit, and clear benefit.
No change
49%The contributor reported no meaningful improvement from the treatment.
No change is different from intolerance. It records lack of benefit, not necessarily a side effect or worsening.
Partially helped
21%Some symptoms improved, but the benefit was incomplete or important problems remained.
This label does not show whether the benefit lasted. Durability requires the full story and treatment timeline.
Helped
22%The contributor reported a clear benefit from rifaximin.
Helped is still a patient-reported outcome. It is not a clinical response rate or a recommendation for another person.
The source behind the data
Real patient reports are structured into symptoms, tests, treatments, and outcomes, then aggregated into the data above.
Anonymous story 1Source: Public Forum
Last reported: Mostly resolved after addressing motility
It helped—then the methane pattern returned.
In their words
“Antibiotics knocked it down every time, then it came back within months. The thing that finally changed the shape of it wasn't another round — it was treating motility like the actual job.”
Anonymous story 2Source: Public Forum
Last reported: Still working on the cause
Repeated courses never ended the loop.
Story summary
Diagnosed with hydrogen SIBO in 2019 and hit by repeated relapses after course after course of rifaximin, this person eventually stepped back and identified a self-reinforcing cycle of stress, microbiome imbalance, and weakened stomach acid — and started treating that instead of just re-clearing the overgrowth.
Anonymous story 3Source: Public Forum
Last reported: Schistosomiasis later diagnosed
The missing diagnosis was not another SIBO treatment.
Story summary
Two years of severe bloating, floating stools, malabsorption, and weight loss persisted despite gallbladder evaluation, SIBO treatment, rifaximin, vancomycin, digestive enzymes, and antiparasitic attempts, until a tropical disease specialist eventually diagnosed schistosomiasis.
Anonymous story 4Source: Public Forum
Last reported: Major improvement after a different finding
Rifaximin did not explain the histamine pattern.
Story summary
Severe histamine intolerance with brain fog, gastritis, and SIBO did not respond to rifaximin, metronidazole, or fluconazole, but incidental testing found pinworms, and albendazole was linked with major improvement in physical function.
Story 1 of 4
What you receive
How GutPattern can help with your rifaximin experience
The page shows the broad rifaximin outcome split. GutPattern can also match those reports to why you took it, what happened, and what else appears in your treatment history.
A closer outcome comparison
Compare rifaximin reports around the reason for use, symptoms, tests, and treatments that matter to you.
Relevant complete stories
Read the experiences behind the numbers instead of relying on a percentage alone.
A Gut Profile you can update
Save your selections, add your own experience, and return as your story changes.
Takes about a minute. Your selections stay private.
Your profile
Claim your free Gut Profile to understand your rifaximin experience.
Bring the reason you took rifaximin, your symptoms, tests, other treatments, personal outcomes, and updates into one profile. Then compare it with relevant stories.
Keep every rifaximin course and outcome together
Compare your details with relevant patient stories
Update the profile when symptoms or treatments change
Patient storyReal Gut Profile
Methane SIBO that kept coming back — what finally held
@methane-mapper · Rifaximin (Xifaxan) outcome patterns
Current statusMostly resolved
In their words · The story
“Antibiotics knocked it down every time, then it came back within months. The thing that finally changed the shape of it wasn't another round — it was treating motility like the actual job.”
Symptoms
ConstipationBloating
Tests & diagnoses
Lactulose breath testMethane SIBO / IMO
Treatments · personal outcomes
7 recordedRifaximin / XifaxanPartially helped
NeomycinPartially helped
Treatments in similar stories
Rifaximin / Xifaxan
Compare your experience
Add why you took rifaximin, what happened, and what else you tried.
Use any details that matter to your story. GutPattern will carry them into the matcher without placing health information in the URL.
Compare outcomes for a similar reason for use
Find complete stories with related symptoms and tests
Continue toward a private Gut Profile you can update
What this dataset can establish
- The cohort includes published stories reporting rifaximin or Xifaxan in treatment history.
- Outcome labels are self-reported and kept separate, including no change and made worse.
- Diagnosis and use-context rows overlap and do not prove why a medicine was prescribed.
- Stories add sequence and detail but do not establish prevalence or causation.
Questions about rifaximin outcomes
What are the reported side effects of rifaximin?
GutPattern's made-worse label is not a clinical side-effect list. MedlinePlus names effects including stomach pain, dizziness, tiredness, headache, muscle tightening, and joint pain, while GutPattern separately shows whether a story reported help, partial help, no change, or worsening.
What do the rifaximin outcomes show?
Across 1,358 outcome-bearing reports in this broad cohort, 22% were rated helped, 21% partially helped, 49% no change, and 8% made worse. These are patient-reported outcomes, not clinical response or adverse-event rates.
Was rifaximin used only for SIBO in these stories?
No. SIBO is the largest reported context, but the cohort is defined by rifaximin or Xifaxan appearing in treatment history. IBS and SIBO subtypes also appear, and diagnosis rows can overlap within one story.
Is Xifaxan the same as rifaximin?
Yes. Xifaxan is a brand name for rifaximin. GutPattern groups both names into the same treatment row and canonical page.
Do these stories prove rifaximin caused a side effect or outcome?
No. The data describes what contributors reported and preserves negative and null outcomes. It cannot prove causation, replace clinical adverse-event data, or determine whether rifaximin is appropriate for someone.